<div id="readability-page-1"><div><p><span></span></p><ul><li><span>Novartis got EU approval for Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria resistant to H1-antihistamines; Phase 3 trials showed reduced itch, hives and urticaria activity.</span><span>1</span></li><li><span>Novartis expanded U.S. capacity in 2026: new San Diego research center, ongoing Cambridge discovery, and three radioligand therapy plants in Denton (TX), Winter Park (FL), and Carlsbad (CA).</span><span>2</span></li><li><span>Novartis (NOVN) is building a 56,200 sq ft API plant in Morrisville, NC, to make APIs for tablets, capsules and RNA therapeutics; it's the seventh facility in its $23B U.S. buildout.</span><span>3</span></li></ul></div></div>

<p>Novartis has received EU approval for Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria resistant to H1-antihistamines, showing reduced itch and hives in Phase 3 trials. The company is expanding its U.S. operations with a new research center in San Diego and three radioligand therapy plants. Additionally, Novartis is constructing a 56,200 sq ft API plant in Morrisville, NC, as part of its $23B U.S. expansion plan.</p>

TradingView

Novartis AG

NOVARTIS AG

iShares Biotechnology ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

VG Health

Key facts: Novartis wins EU OK for Rhapsido; builds Morrisville API site